DRD1 and cancer: However, many DR‐targeting drugs are already FDA‐approved for treatment of neuropsychiatric disorders and hypertension, including D1R agonists, so the investigation of these medications for repurposing as cancer treatments represents a promising and potentially cost‐effective treatment strategy.